In 2008, Timothy P. Walbert was named president and chief executive officer of Horizon Pharma and, using free wi-fi and parking at neighborhood coffee shops, broke biotechnology industry norms by moving Horizon Pharma from the Bay Area to Chicago. That humble beginning evolved into a journey where the company has grown to more than 900 employees and an expected more than $1 billion in 2016 net sales in less than eight years.
It’s been an incredible ride for Tim. Prior to joining Horizon, Tim commercialized Celebrex and led the global development and launch of HUMIRA, the world’s best-selling brand at over $14 billion annually. Tim took Horizon public in 2011, overcoming a three-year volatile marketplace and has since continued to lead the company to dramatic net sales and employee growth.
Tim’s passion for the biopharmaceutical industry was sparked after learning as a junior in college that he has an autoimmune disease similar to rheumatoid arthritis. As a patient, he has personally benefited from many of the medicines he has commercialized. Tim is very active in the Chicago healthcare community, currently serving as co-chairman of the board of MATTER and chairman of the Illinois Biotechnology Industry Organization. Tim also devotes significant time to industry advocacy organizations and sits on the board of BIO (Biotechnology Innovation Organization) and Pharmaceutical Research and Manufacturers of America (PhRMA). Tim is also chairman of the board of Egalet Corporation and sits on the boards of Sucampo Pharmaceuticals and XOMA Corp.
ContextMedia, Pritzker Group Venture Capital, and MATTER are proud to host Tim for our next Tales from the Trenches. ContextMedia co-founder and CEO Rishi Shah will interview Tim about his time at the helm of Horizon Pharma, as well as his years of experience in senior leadership positions at pharmaceutical giants Abbott, now Abbvie, G.D. Searle & Company, Merck & Co., Inc., and Wyeth.
© Illinois Science and Technology Coalition
Illustration by Dieter Braun